Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (16183)	1/30/2003 8:59:28 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 17367

News this morning...but I think the Barron's article this week put a damper on this stock.. "XOMA Initiates Phase II Clinical Trial with Raptiva -- Efalizumab -- in Psoriatic Arthritis Thursday January 30, 7:30 am ET BERKELEY, Calif.--(BUSINESS WIRE)--Jan. 30, 2003--XOMA Ltd. (Nasdaq:XOMA - News) announced today the initiation of a Phase II clinical trial that will evaluate Raptiva(TM) (efalizumab) in patients with active and progressive psoriatic arthritis (PsA). With the recent filing of a Biologics License Application (BLA), Raptiva(TM) is currently in the review process by the U.S. Food and Drug Adminstration (FDA) for the treatment of moderate-to-severe plaque psoriasis, and is under evaluation in a Phase II trial for the treatment of rheumatoid arthritis (RA